Real-World Treatment Patterns and Survival Among Patients with Stage I-III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment.
Soo Jin SeungDaniel MoldaverShazia HassanIqra SyedMaryKate ShanahanGeoffrey LiuPublished in: Oncology and therapy (2024)
In Ontario, between 2010 and 2019, uptake of adjuvant therapy was low among patients with resected NSCLC, despite such therapy being associated with improved survival. Patients assumed to have recurred/relapsed had markedly reduced mOS, regardless of subsequent therapy, compared with those who did not relapse/recur. Novel peri-adjuvant treatment options are needed to enhance outcomes after lung resection.
Keyphrases
- small cell lung cancer
- ejection fraction
- prognostic factors
- end stage renal disease
- early stage
- newly diagnosed
- free survival
- minimally invasive
- acute lymphoblastic leukemia
- lymph node
- high grade
- diffuse large b cell lymphoma
- quantum dots
- combination therapy
- gold nanoparticles
- advanced non small cell lung cancer
- patient reported outcomes
- bone marrow
- atrial fibrillation
- epidermal growth factor receptor
- highly efficient
- surgical site infection
- smoking cessation